Non-tuberculous Mycobacterial Lung Disease
📧 Sign up to get email alerts when something new happens for Non-tuberculous Mycobacterial Lung Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Clinical Characteristics and Immune Escape Mechanism of Nontuberculous Mycobacterial Lung Disease in South China
This clinical trial from Sun Yat-sen University investigates clinical characteristics and immune escape mechanisms of non-tuberculous mycoba…
-
EMA approval · 2025-10-14EMA Authorised: Arikayce liposomal (amikacin sulfate) — Insmed Netherlands B.V.
The EMA authorised Arikayce liposomal amikacin sulfate for use in respiratory tract infections, with orphan medicine designation; the market…
-
FDA approval · 2023-02-10FDA Approved: ARIKAYCE — Supplemental Application (Insmed Incorporated)
FDA approved a supplemental application for ARIKAYCE (amikacin liposome inhalation suspension) from Insmed Incorporated. This action updates…
-
FDA approval · 2020-10-19FDA Approved: ARIKAYCE — Supplemental Application (Insmed Incorporated)
The FDA approved a supplemental application for ARIKAYCE (amikacin liposome inhalation suspension) from Insmed Incorporated. The action upda…